Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Director Eric W. Roberts of CalciMedica, Inc. (NASDAQ:CALC) recently purchased 5,076 shares of common stock at a weighted average price of $2.8977, in a transaction valued at $14,708. The prices for the purchase ranged from $2.80 to $2.90. The purchase comes as the stock has shown strong momentum, gaining nearly 19% in the past week according to InvestingPro data.
The transaction, which occurred on August 15, 2025, was reported in a Form 4 filing with the Securities and Exchange Commission on August 19, 2025. While the company maintains strong liquidity with a current ratio of 5.45, InvestingPro analysis indicates rapid cash burn and weak overall financial health.
Following the transaction, Roberts directly holds 164,706 shares. Roberts also indirectly holds 54,399 shares by FMTC Custodian - Roth IRA FBO Eric W. Roberts, 49,894 shares By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares By IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares By Valence Investments SPV IV, LLC, 66,228 shares By Valence Investments SPV V, LLC and 316,109 shares By Valence Investments SPV VI, LLC.
In other recent news, CalciMedica Inc. has outlined the design of its Phase 2 KOURAGE trial for Auxora, a treatment for acute kidney injury (AKI) with respiratory failure. The trial’s details were published in the American Journal of Nephrology and include preclinical data indicating a significant increase in the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from the CARDEA trial showed a 62.7% relative reduction in mortality among COVID-19 patients with AKI treated with Auxora compared to those who received a placebo. In another development, CalciMedica announced a change in its independent registered public accounting firm due to a merger. Moss Adams LLP, the previous firm, merged with Baker Tilly US, LLP, leading to Baker Tilly’s (NYSE:TLYS) appointment as the new auditor. The company’s Board of Directors’ Audit Committee approved this decision. The audit report from Moss Adams for the year ending December 31, 2024, was issued without adverse opinions or modifications, and no disagreements were reported regarding accounting practices or financial disclosures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.